PT-141 (Bremelanotide)
PT-141 (Bremelanotide)
Also known as: Bremelanotide, Vyleesi, PT141
Overview
Key Facts
Primary Goal: Research and therapeutic applications of PT-141 (Bremelanotide)
Agonizes melanocortin-4 receptors (MC4R) in the hypothalamus and limbic system to modulate sexual arousal pathways. Activates central dopaminergic and oxytocinergic signaling involved in sexual motivation.
Dosing Information
~2.7 hours
500–1750 mcg
as needed, at least 45 minutes before anticipated activity
As needed (no more than once per 24 hours, max 8 doses per month per FDA labeling)
Benefits
- FDA-approved for hypoactive sexual desire disorder in premenopausal women
- Acts centrally to enhance sexual desire and arousal
- Effective in both men and women in research settings
- Does not require daily dosing
- Works through a unique non-vascular mechanism
Side Effects
Mechanism of Action
Agonizes melanocortin-4 receptors (MC4R) in the hypothalamus and limbic system to modulate sexual arousal pathways
Activates central dopaminergic and oxytocinergic signaling involved in sexual motivation
Does not act on peripheral vasculature like PDE5 inhibitors, instead targeting central nervous system desire pathways
Contraindications
Do not use this peptide if any of the following apply:
- Uncontrolled hypertension or significant cardiovascular disease
- Concurrent use with naltrexone (opioid antagonist)
- Pregnancy or breastfeeding
- Known hypersensitivity to bremelanotide
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Research Summary
Bremelanotide was approved by the FDA in June 2019 under the brand name Vyleesi for HSDD in premenopausal women, following two Phase III RECONNECT trials. These studies showed statistically significant improvements in sexual desire and reductions in distress compared to placebo. Earlier Phase II research in men also demonstrated pro-erectile effects, though development focused on the female indication. It remains the only FDA-approved on-demand treatment for HSDD.
Frequently Asked Questions
Common questions about PT-141 (Bremelanotide)
UK-Specific Information
Exclusive data points and guidance for UK residents using PT-141 (Bremelanotide)
UK Lab Testing
UK Lab Testing
Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
Ac-SDKP
Research and therapeutic applications of Ac-SDKP
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.
Share on TikTok
Generate a trackable link to share this peptide information on TikTok